Please assess the completion status of the following clinical trial:

Trial Title: A Study of ALKS 3831 in Adults With Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 to 50 years, inclusive~* Body mass index (BMI) of 17-30 kg/m2, inclusive~* Diagnosis of schizophrenia that is clinically stable~Exclusion Criteria:~* Initiated 1st antipsychotic treatment within the past 12 months and/or has had symptoms lasting \<2 years~* Current diagnosis of alcohol or drug use disorder, moderate or severe~* Clinically significant or unstable medical illness, condition, or disorder~* Pregnant or breastfeeding~* Significant changes in diet or exercise regimen or plans to join a weight management program during the study~* Opioid medications taken within 14 days and/or need to take opioid medication during the study period~* History of hypersensitivity to or intolerance of olanzapine~* Use of olanzapine, clozapine, mesoridazine, chlorpromazine, or thioridazine for more than 1 week during the past year

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Low Dose (Type: EXPERIMENTAL): Olanzapine + low dose samidorphan tablets taken once daily
- Medium Dose (Type: EXPERIMENTAL): Olanzapine + medium dose samidorphan tablets taken once daily
- High Dose (Type: EXPERIMENTAL): Olanzapine + high dose samidorphan tablets taken once daily
- Placebo (Type: PLACEBO_COMPARATOR): Olanzapine + placebo tablets taken once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).